Entrada Therapeutics (TRDA) Competitors $5.28 -0.05 (-0.94%) Closing price 04:00 PM EasternExtended Trading$5.36 +0.08 (+1.42%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRDA vs. KALV, AKBA, DAWN, TNGX, IMTX, NRIX, OCS, NAGE, VALN, and GYREShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include KalVista Pharmaceuticals (KALV), Akebia Therapeutics (AKBA), Day One Biopharmaceuticals (DAWN), Tango Therapeutics (TNGX), Immatics (IMTX), Nurix Therapeutics (NRIX), Oculis (OCS), Niagen Bioscience (NAGE), Valneva (VALN), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Its Competitors KalVista Pharmaceuticals Akebia Therapeutics Day One Biopharmaceuticals Tango Therapeutics Immatics Nurix Therapeutics Oculis Niagen Bioscience Valneva Gyre Therapeutics Entrada Therapeutics (NASDAQ:TRDA) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Do insiders & institutionals have more ownership in TRDA or KALV? 86.4% of Entrada Therapeutics shares are owned by institutional investors. 8.1% of Entrada Therapeutics shares are owned by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings and valuation, TRDA or KALV? Entrada Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$210.78M0.95$65.63M-$1.78-2.97KalVista PharmaceuticalsN/AN/A-$183.44M-$3.94-3.56 Which has more risk & volatility, TRDA or KALV? Entrada Therapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Is TRDA or KALV more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. Entrada Therapeutics' return on equity of -17.81% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics-92.30% -17.81% -14.55% KalVista Pharmaceuticals N/A -134.07%-82.65% Do analysts rate TRDA or KALV? Entrada Therapeutics currently has a consensus price target of $25.67, indicating a potential upside of 386.11%. KalVista Pharmaceuticals has a consensus price target of $26.43, indicating a potential upside of 88.64%. Given Entrada Therapeutics' higher probable upside, equities research analysts clearly believe Entrada Therapeutics is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media prefer TRDA or KALV? In the previous week, KalVista Pharmaceuticals had 19 more articles in the media than Entrada Therapeutics. MarketBeat recorded 22 mentions for KalVista Pharmaceuticals and 3 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.18 beat KalVista Pharmaceuticals' score of 0.76 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KalVista Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEntrada Therapeutics beats KalVista Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$200.85M$3.12B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-2.9721.3074.5925.92Price / Sales0.95240.30449.5483.33Price / Cash3.2945.3337.0859.91Price / Book0.469.6112.156.29Net Income$65.63M-$53.29M$3.28B$270.85M7 Day Performance-0.19%0.29%0.98%3.36%1 Month Performance2.33%8.91%7.20%6.41%1 Year Performance-64.47%13.14%63.06%28.26% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics2.7195 of 5 stars$5.28-0.9%$25.67+386.1%-64.1%$200.85M$210.78M-2.97110News CoverageKALVKalVista Pharmaceuticals4.0313 of 5 stars$15.96+0.9%$26.29+64.7%+38.2%$796.38MN/A-4.33100Trending NewsEarnings ReportAnalyst ForecastInsider TradeAKBAAkebia Therapeutics3.8087 of 5 stars$3.13+5.7%$6.75+115.7%+107.6%$784.83M$160.18M-18.41430Positive NewsDAWNDay One Biopharmaceuticals3.0921 of 5 stars$7.47-1.1%$25.29+238.5%-47.7%$773.36M$131.16M-7.8660Positive NewsTNGXTango Therapeutics1.8416 of 5 stars$6.81-1.9%$10.50+54.2%-29.4%$772.15M$42.07M-5.1290News CoveragePositive NewsInsider TradeIMTXImmatics2.92 of 5 stars$5.81-7.2%$14.67+152.4%-49.4%$760.90M$168.65M-8.94260Positive NewsNRIXNurix Therapeutics2.3862 of 5 stars$9.70-2.1%$29.07+199.7%-61.3%$757.61M$54.55M-3.72300News CoveragePositive NewsOCSOculis3.3025 of 5 stars$17.25+0.2%$35.75+107.2%+43.5%$751.86MN/A-6.462Short Interest ↓NAGENiagen Bioscience2.0297 of 5 stars$9.45+0.4%$13.42+42.0%N/A$750.47M$99.60M45.00120Analyst DowngradeVALNValneva2.783 of 5 stars$8.52-1.5%$15.00+76.1%+31.1%$743.27M$183.52M-8.69700Short Interest ↓Gap DownGYREGyre Therapeutics1.672 of 5 stars$7.89+2.6%$18.00+128.1%-41.1%$740.65M$105.76M789.7940News CoveragePositive NewsAnalyst Revision Related Companies and Tools Related Companies KalVista Pharmaceuticals Alternatives Akebia Therapeutics Alternatives Day One Biopharmaceuticals Alternatives Tango Therapeutics Alternatives Immatics Alternatives Nurix Therapeutics Alternatives Oculis Alternatives Niagen Bioscience Alternatives Valneva Alternatives Gyre Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRDA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRDA Stock Alerts